Grant of Restricted Stock Units

Summary by AI BETAClose X

Manx Financial Group PLC has announced the grant of 929,792 Restricted Stock Units (RSUs) to selected executives and senior management, with a performance period ending December 31, 2028, contingent on continued employment and meeting performance conditions related to profit before tax, total shareholder return, and the new deposit system. Notably, director Douglas Grant received 253,593 RSUs, potentially increasing his holding to 2.88% of the enlarged share capital, while director James Smeed was granted 160,542 RSUs, potentially bringing his stake to 0.53%, and PDMR Haseeb Qureshi received 164,315 RSUs, also potentially reaching 0.53%. These awards are designed to incentivize and retain key personnel and align their interests with shareholders.

Disclaimer*

Manx Financial Group PLC
30 September 2026
 

FOR IMMEDIATE RELEASE                                                       30 September 2026

 

 

Manx Financial Group PLC (the ‘Company’ or the ‘Group’)

Grant of Restricted Stock Units

Manx Financial Group PLC (AIM: MFX), the diversified UK banking and financial services group, announces that the Remuneration Committee has approved the grant of awards over an aggregate of 929,792 ordinary shares of no par value in the Company in the form of Restricted Stock Units (“RSUs”) under the Manx Financial Group PLC Restricted Stock Unit Plan 2022 as previously approved by Shareholders.

In approving the awards, the Remuneration Committee acted independently, and the Executive Directors did not participate in the decision-making process in respect of their proposed awards.

The awards have been made to selected executives and senior management of the Group and are intended to support the retention and incentivisation of key individuals, align participants with the interests of shareholders and promote the delivery of the Group’s long-term strategic objectives.

The RSUs are subject to a performance period ending 31 December 2028 and will vest subject to continued employment and the satisfaction of applicable performance conditions. The performance framework comprises cumulative profit before tax, absolute total shareholder return/share price performance and delivery of the Group’s new deposit system.

The awards have a nil exercise price and are subject to the terms of the Company’s Restricted Stock Unit Plan 2022, as amended from time to time.

 

Douglas Grant, a director and PDMR of the Company, was issued 253,593 RSUs. He currently owns 3,372,638 Ordinary Shares in the Company representing a holding of 2.70%. Following the grant, he would hold a total of 3,626,231 Ordinary Shares on a fully diluted basis, assuming full vesting of the RSUs granted under the Plan, representing 2.88% of the Company’s enlarged share capital on that basis.

 

James Smeed, a director and PDMR of the Company, was issued 160,542 RSUs. He currently owns 505,854 Ordinary Shares in the Company representing a holding of 0.40%. Following the grant, he would hold a total of 666,396 Ordinary Shares on a fully diluted basis, assuming full vesting of the RSUs granted under the Plan, representing 0.53% of the Company’s enlarged share capital on that basis.

 

Haseeb Qureshi, a PDMR of the Company, was issued 164,315 RSUs. He currently owns 505,854 Ordinary Shares in the Company representing a holding of 0.40%. Following the grant, he would hold a total of 670,169 Ordinary Shares on a fully diluted basis, assuming full vesting of the RSUs granted under the Plan, representing 0.53% of the Company’s enlarged share capital on that basis.

 

For further information, please contact:

Manx Financial Group PLC

Beaumont Cornish Limited

Shore Capital

 

Tavistock Communications Limited

Denham Eke

Roland Cornish/

James Biddle

Toby Gibbs/

Oliver Jackson

 

Simon Hudson/

Adam Baynes

Tel: +44 (0) 1624 694694

Tel: +44 (0) 20 7628 3396

Tel: +44 (0) 20 7408 4090

 

Tel: +44 (0) 20 7920 3150

mfg@tavistock.co.uk

 

About Manx Financial

 

Manx Financial Group (AIM: MFX) is a diversified UK banking and financial services group with a proud Manx heritage. The Group holds Isle of Man and UK banking licences, allowing it to provide flexible funding solutions across both territories focused on SME lending. Knowledge of the SME sector has enabled MFX to build a portfolio of valuable subsidiaries, from start-ups to selective and accretive acquisitions, which are creating significant value for shareholders. These entrepreneurial subsidiaries are grouped under our entrepreneurial subsidiary Manx Ventures Limited.

 

Nominated Adviser

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

Distribution

This announcement has been notified via a Regulatory Information Service and it is not authorised for distribution into North America or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of that jurisdiction.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings